Jade Biosciences To Present New Preclinical Safety, Translational Data For Immunoglobulin A Nephropathy Candidate JADE101 American Society of Nephrology Kidney Week

SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("the Company" or "Jade"), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it will present new preclinical safety and translational data for JADE101, its lead investigational candidate for immunoglobulin A nephropathy (IgAN), during two poster sessions at the American Society of Nephrology (ASN) Kidney Week 2025, taking place November 5–9 in Houston, Texas.

JADE101 is designed to selectively inhibit A PRoliferation-Inducing Ligand (APRIL) in patients with IgAN, an autoimmune disease that leads to end-stage kidney disease over the lifetime of most patients. The therapy is engineered with properties intended to achieve the full efficacy of APRIL pathway inhibition with patient-friendly subcutaneous dosing, based on its differentiated preclinical pharmacokinetic and pharmacodynamic profile in non-human primates. JADE101 is currently being evaluated in a Phase 1 healthy volunteer clinical trial, with interim data expected in the first half of 2026.